Brief: Immuneonco Biopharmaceuticals Announces Registrational Strategy In Collaboration With Instil
16/09/2024 17:48
Sept 16 (Reuters) - ImmuneOnco Biopharmaceuticals
Shanghai Inc 1541.HK :
* GLOBAL REGISTRATIONAL STRATEGY IN COLLABORATION WITH
INSTIL FOR
PD- L1XVEGF BISPECIFIC ANTIBODY
* ACCELERATING DEVELOPMENT OF PD- L1XVEGF BISPECIFIC
ANTIBODY DRUG
Further company coverage: 1541.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Instil Bio
See all newsInstil Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Instil Bio Q2 net loss narrows on lower R&D spending, restructuring charges
Brief: Instil Bio Q2 Basic EPS USD -0.63
Instil Bio, Inc. expected to post a loss of 43 cents a share - Earnings Preview
Instil Bio Q1 net loss narrows on lower R&D expenses